Q-omics provides the consensus-scored ETV7 profile across patient tissues and cancer cell-line models. ETV7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ETV7 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ETV7 RNA expression shows 15,969 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRC, and TGCT as cancer lineages where ETV7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETV7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETV7 survival associations across molecular data types. ETV7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETV7 RNA expression–survival associations across cancer types. High ETV7 expression shows unfavorable associations in UVM and ACC, but favorable associations in SKCM, BLCA, CESC and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ETV7 RNA expression.
This table summarizes ETV7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ETV7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETV7 shows higher tumor expression in KIRC, THCA, COAD, STAD, BRCA and KIRP. The KIRC box plot shows higher ETV7 RNA expression in tumor versus normal tissue (log2 FC = +2.365, t-test p < 0.001).
This table shows molecular features associated with ETV7 in patient tissues and cancer cell lines. In patient samples, ETV7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ETV7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
